These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12833653)

  • 1. PEG-sTNF-RI. Amgen.
    Darlington C
    Curr Opin Investig Drugs; 2003 May; 4(5):583-7. PubMed ID: 12833653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.
    Edwards CK
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I73-81. PubMed ID: 10577978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy.
    McComb J; Gould T; Chlipala E; Sennelo G; Frazier J; Kieft G; Seely J; Edwards CK; Bendele A
    J Rheumatol; 1999 Jun; 26(6):1347-51. PubMed ID: 10381054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats.
    Bendele AM; McComb J; Gould T; Frazier J; Chlipala E; Seely J; Kieft G; Edwards CK
    Clin Exp Rheumatol; 1999; 17(5):553-60. PubMed ID: 10544838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases.
    Edwards CK; Martin SW; Seely J; Kinstler O; Buckel S; Bendele AM; Ellen Cosenza M; Feige U; Kohno T
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1315-36. PubMed ID: 14499710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats.
    Bendele AM; McComb J; Gould T; Frazier J; Chlipala ES; Seely J; Kieft G; Wolf J; Edwards CK
    Inflamm Res; 1999 Aug; 48(8):453-60. PubMed ID: 10493163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
    Glossop JR; Dawes PT; Nixon NB; Mattey DL
    Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
    Akiyama Y; Mimura T
    Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
    Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
    Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDP-870. Celltech/Pfizer.
    Rose-John S; Schooltink H
    Curr Opin Investig Drugs; 2003 May; 4(5):588-92. PubMed ID: 12833654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats.
    Feige U; Hu YL; Gasser J; Campagnuolo G; Munyakazi L; Bolon B
    Cell Mol Life Sci; 2000 Sep; 57(10):1457-70. PubMed ID: 11078023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
    Mathsson L; Lampa J; Mullazehi M; Rönnelid J
    Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A; Hasegawa K; Suguro T; Koshihara Y
    J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus.
    Kerwin BA; Chang BS; Gegg CV; Gonnelli M; Li T; Strambini GB
    Protein Sci; 2002 Jul; 11(7):1825-33. PubMed ID: 12070334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etanercept].
    Mühlhäuser U; Münzel F; Eschenhagen T
    Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1775-8. PubMed ID: 12934172
    [No Abstract]   [Full Text] [Related]  

  • 18. Etanercept in arthritis.
    Scott DL
    Int J Clin Pract; 2005 Jan; 59(1):114-8. PubMed ID: 15707475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept (Enbrel) -- an update.
    Goffe B
    Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
    Zhou H
    J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.